相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma (SUN-CK phase II trial): Safety, efficacy, and updated translational results.
Cindy Neuzillet et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Second-line chemotherapy in advanced biliary cancer: a systematic review
A. Lamarca et al.
ANNALS OF ONCOLOGY (2014)
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
L. Fornaro et al.
BRITISH JOURNAL OF CANCER (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin
Shengli He et al.
JOURNAL OF CHEMOTHERAPY (2014)
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
David Malka et al.
LANCET ONCOLOGY (2014)
Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis
Rui Yang et al.
ANTI-CANCER DRUGS (2013)
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
Eiichiro Suzuki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Second-line therapy in advanced biliary tract cancer: What should be the standard?
Stefano Cereda et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Outcome of second-line chemotherapy for biliary tract cancer
John Bridgewater et al.
EUROPEAN JOURNAL OF CANCER (2013)
Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study
Thomas Walter et al.
EUROPEAN JOURNAL OF CANCER (2013)
A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study
Jun Ho Yi et al.
EUROPEAN JOURNAL OF CANCER (2012)
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
Takashi Sasaki et al.
INVESTIGATIONAL NEW DRUGS (2012)
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
Jeeyun Lee et al.
LANCET ONCOLOGY (2012)
Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer
Kyu-Hyoung Lim et al.
ONCOLOGY (2012)
Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer
Takashi Sasaki et al.
INVESTIGATIONAL NEW DRUGS (2011)
A Phase II Study of Outpatient Biweekly Gemcitabine-Oxaliplatin in Advanced Biliary Tract Carcinomas
Amal Halim et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
C. Bengala et al.
BRITISH JOURNAL OF CANCER (2010)
Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study
Atul Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer
Suee Lee et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2009)
Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers
Maria S. Pino et al.
ONCOLOGY (2009)
S-1 Monotherapy in Patients with Advanced Biliary Tract Cancer
Takashi Sasaki et al.
ONCOLOGY (2009)
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
Mi-Jung Kim et al.
BMC CANCER (2008)
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
T. Andre et al.
BRITISH JOURNAL OF CANCER (2008)
Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas
Bernard Paule et al.
ONCOLOGY (2007)
Phase II study of erlotinib in patients with advanced biliary cancer
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma:: a GERCOR study
T André et al.
ANNALS OF ONCOLOGY (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
